Conference
First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression.
Authors
Gettinger SN; Hellmann MD; Shepherd FA; Antonia SJ; Brahmer JR; Chow LQM; Goldman JW; Juergens RA; Borghaei H; Ready N
Volume
33
Pagination
pp. 8025-8025
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2015
DOI
10.1200/jco.2015.33.15_suppl.8025
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X